+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Pipeline Review, H1 2019

  • ID: 4767150
  • Drug Pipelines
  • April 2019
  • Region: Global
  • 78 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AveXis Inc
  • Biogen Inc
  • Exicure Inc
  • F. Hoffmann-La Roche Ltd
  • Ionis Pharmaceuticals Inc
  • Novartis AG
  • MORE
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Pipeline Review, H1 2019

Summary

According to the recently published report 'Survival Motor Neuron Protein - Pipeline Review, H1 2019'; Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) pipeline Target constitutes close to 18 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.

Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Survival of motor neuron or survival motor neuron (SMN) is a protein encoded by the SMN1 and SMN2 genes. The SMN complex plays a catalyst role in the assembly of small nuclear ribonucleoproteins (snRNPs). They play an important role in the splicing of cellular pre-mRNAs. They ensure the correct splicing of U12 intron-containing genes that is important for normal motor and proprioceptive neurons development. They are required for resolving RNA-DNA hybrids created by RNA polymerase II. They play a role in the metabolism of small nucleolar ribonucleoprotein.

The report 'Survival Motor Neuron Protein - Pipeline Review, H1 2019' outlays comprehensive information on the Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1, 1 and 7 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 5 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System and Respiratory which include indications Spinal Muscular Atrophy (SMA) and Cystic Fibrosis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2)
  • The report reviews Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AveXis Inc
  • Biogen Inc
  • Exicure Inc
  • F. Hoffmann-La Roche Ltd
  • Ionis Pharmaceuticals Inc
  • Novartis AG
  • MORE
Introduction

Report Coverage

Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Overview

Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Companies Involved in Therapeutics Development

AveXis Inc

Biogen Inc

Exicure Inc

F. Hoffmann-La Roche Ltd

Ionis Pharmaceuticals Inc

Novartis AG

Sarepta Therapeutics Inc

Spotlight Innovation Inc

Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Drug Profiles

ALB-111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotide to Activate SMN2 for Spinal Muscular Atrophy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotides to Activate SMN2 for Spinal Muscular Atrophy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIIB-089 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

branaplam - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate SMN for Spinal Muscular Atrophy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IONISENAC-2.5Rx - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LDN-5178 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotide to Activate SMN2 for Spinal Muscular Atrophy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onasemnogene abeparvovec - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PMO-25 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

risdiplam - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules 2 to Activate SMN2 for Spinal Muscular Atrophy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Spinal Muscular Atrophy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate SMN2 for Spinal Muscular Atrophy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate SMN2 for Spinal Muscular Atrophy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STL-182 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Dormant Products

Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Discontinued Products

Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Product Development Milestones

Featured News & Press Releases

Apr 03, 2019: ICER Issues Final Report on Zolgensma, provides Policy recommendations related to Pricing and Coverage of treatments for Spinal Muscular Atrophy

Apr 01, 2019: AveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, Colorado

Mar 27, 2019: Chugai receives Orphan Drug Designation for Risdiplam in Spinal Muscular Atrophy

Feb 18, 2019: Gene Therapy Firm AveXis to expand in Durham County adding 200 jobs and $60 Million in investment

Feb 01, 2019: First phase 3 gene therapy trial in spinal muscular atrophy at The John Walton Muscular Dystrophy Centre

Jan 08, 2019: Genentech, Roche and PTC Therapeutics provide update on Regulatory Filing for Risdiplam

Dec 19, 2018: Roche gets PRIME designation for SMA drug in Europe

Dec 03, 2018: Novartis announces FDA filing acceptance and Priority Review of AVXS-101, a one-time treatment designed to address the genetic root cause of SMA Type 1

Nov 05, 2018: Novartis provides update on AVXS101

Oct 03, 2018: Roche announces new data for Risdiplam in spinal muscular atrophy(SMA) at the World Muscle Society Congress

Oct 03, 2018: Risdiplam Demonstrates Preliminary Evidence of Clinical Benefit in Type 1, 2, & 3 Spinal Muscular Atrophy Patients

Jul 24, 2018: Spotlight Innovation spinal muscular atrophy research collaborator professor Kevin Hodgetts receives $300,000 grant from Cure SMA

Jun 16, 2018: Updated Preliminary Data from SMA FIREFISH Program in Type 1 Babies Presented at the CureSMA Conference

Jun 14, 2018: Exicure to Present Data at the Cure Spinal Muscular Atrophy Annual Conference in Dallas

May 08, 2018: AveXis Issues Community Statement on the SPR1NT Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Indication, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Number of Products under Investigation by Universities/Institutes, H1 2019

Products under Investigation by Universities/Institutes, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Pipeline by AveXis Inc, H1 2019

Pipeline by Biogen Inc, H1 2019

Pipeline by Exicure Inc, H1 2019

Pipeline by F. Hoffmann-La Roche Ltd, H1 2019

Pipeline by Ionis Pharmaceuticals Inc, H1 2019

Pipeline by Novartis AG, H1 2019

Pipeline by Sarepta Therapeutics Inc, H1 2019

Pipeline by Spotlight Innovation Inc, H1 2019

Dormant Projects, H1 2019

Discontinued Products, H1 2019

List of Figures

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Top 10 Indications, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AveXis Inc
  • Biogen Inc
  • Exicure Inc
  • F. Hoffmann-La Roche Ltd
  • Ionis Pharmaceuticals Inc
  • Novartis AG
  • Sarepta Therapeutics Inc
  • Spotlight Innovation Inc
Note: Product cover images may vary from those shown
Adroll
adroll